Zealand Pharma A/S (company was delisted NASDAQ) (ZEAL)
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General